10,903 Shares in NxStage Medical, Inc. (NASDAQ:NXTM) Acquired by KCG Holdings Inc.

KCG Holdings Inc. purchased a new position in NxStage Medical, Inc. (NASDAQ:NXTM) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,903 shares of the medical device company’s stock, valued at approximately $293,000.

A number of other institutional investors also recently added to or reduced their stakes in NXTM. SG Americas Securities LLC acquired a new stake in shares of NxStage Medical during the first quarter worth $140,000. Ameritas Investment Partners Inc. acquired a new stake in shares of NxStage Medical during the first quarter worth $148,000. Menta Capital LLC acquired a new stake in shares of NxStage Medical during the first quarter worth $212,000. Trexquant Investment LP acquired a new stake in shares of NxStage Medical during the first quarter worth $227,000. Finally, Karp Capital Management Corp acquired a new stake in shares of NxStage Medical during the first quarter worth $256,000. 91.82% of the stock is owned by institutional investors.

NxStage Medical, Inc. (NASDAQ:NXTM) traded up 0.03% during midday trading on Friday, hitting $29.25. 2,297,868 shares of the stock were exchanged. NxStage Medical, Inc. has a 12 month low of $20.45 and a 12 month high of $30.80. The firm’s 50 day moving average price is $25.63 and its 200 day moving average price is $25.95. The company’s market cap is $1.93 billion.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm had revenue of $92.20 million for the quarter, compared to the consensus estimate of $96.47 million. During the same quarter in the previous year, the firm earned ($0.03) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. On average, equities research analysts forecast that NxStage Medical, Inc. will post ($0.04) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “10,903 Shares in NxStage Medical, Inc. (NASDAQ:NXTM) Acquired by KCG Holdings Inc.” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/19/10903-shares-in-nxstage-medical-inc-nasdaqnxtm-acquired-by-kcg-holdings-inc-updated-updated-updated.html.

NXTM has been the topic of a number of recent research reports. Craig Hallum initiated coverage on shares of NxStage Medical in a report on Tuesday, June 27th. They issued a “buy” rating and a $32.00 price objective on the stock. Canaccord Genuity restated a “buy” rating and issued a $32.00 price objective on shares of NxStage Medical in a report on Monday, May 8th. BidaskClub upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating in a report on Friday, June 30th. Jefferies Group LLC cut their price objective on shares of NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th. Finally, Northland Securities cut shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a report on Thursday, May 4th. One investment analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. NxStage Medical has an average rating of “Hold” and a consensus price target of $30.29.

In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $23.14, for a total transaction of $80,990.00. Following the sale, the senior vice president now owns 17,270 shares of the company’s stock, valued at approximately $399,627.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $25.19, for a total transaction of $25,190.00. Following the sale, the president now directly owns 75,903 shares in the company, valued at approximately $1,911,996.57. The disclosure for this sale can be found here. In the last ninety days, insiders sold 53,900 shares of company stock worth $1,429,518. Insiders own 4.70% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

What are top analysts saying about NxStage Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NxStage Medical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit